137
Transforming growth factor-beta 1 and TbetaRII/Smad3
signalling pathway regulates the vascular endothelial growth
factor expression of tumour-associated macrophages in oral
squamous cell carcinoma
K.X. Yan
∗
, C.J. Li, H.B. Sun, L. Wang, L.J. Li
West China School of Stomatology, Sichuan University,
Chengdu, China
Objectives:
In this study, we aim to investigate the correlation
between macrophages and several prognosis-associated clinic-
pathological indicators and more importantly, how transforming
growth factor-beta 1 (TGF- 1) acts on the vascular endothelial
growth factor (VEGF) expression of macrophages.
Methods:
72 paraffin-embedded oral squamous cell carci-
noma (OSCC) samples were randomly selected for CD68 and
CD31 immunohistochemical staining to study the relationship of
macrophages quantity, microvascular density (MVD) and clini-
copathological features. Fresh OSCC tissues, metastatic lymph
nodes and non-metastatic lymph nodes were collected during
the surgery for CD68, CD206, iNOS and VEGF staining as
well as VEGF quantitative analysis. Macrophages induced from
C57BL/6J mouse bone marrow cells were stimulated by Cal
27 cells condition medium (CM) with or without neutralising
antibodies for TGF- 1 and T RII. Western blot, enzyme-linked
immunosorbent assay and quantitative real-time polymerase chain
reaction were applied to assess the expression of vascular endothe-
lial growth factor (VEGF) indifferent conditions.
Results:
High number of macrophages was directly correlated to
lower pathological differentiation degree, later of clinical stage
and lower survival rate. MVD also has positive correlation with
clinical stage and macrophages number. What’s more, OSCC-
associated macrophages expressed more VEGF than macrophages
in health lymph nodes. But when the TGF- 1 in Cal 27 cells CM
and the T RII in macrophages were neutralised or the Smad3 was
inhibited, the VEGF expression was down regulated too.
Conclusion:
Via the T RII/Smad3 signalling pathway, TGF- 1
can promote the OSCC-associated macrophages to secrete more
VEGF, an angiogenic factor of great importance.
http://dx.doi.org/10.1016/j.ijom.2017.02.475Surgical management and follow-up of lateral skull base
tumours — an eight-year review
H.Y. Yang
Peking University Shenzhen Hospital, China
Background:
Lateral skull base tumour is a challenge for oral and
maxillofacial surgeons.
Objectives:
The purpose of this article is to describe the diagnostic
evaluation and surgical approaches to lateral skull base tumours
(LSBTs).
Methods:
The study is a retrospective review of 21 patients
diagnosed with tumours involving the lateral skull base (8 with
malignant diseases and 13 with benign lesions) and surgically
treated over an eight-year period.
Findings:
The transparotid-transmandibular (38%) was the most
commonly performed surgical procedures followed by the trans-
mandibular (24%), the transmaxillary (24%), the transcervical
approach (10%) and the combined approach (4%). The surgi-
cal procedures were uneventful and there were no postoperative
mortalities. Complications were encountered in eight cases, and
morbidity was not remarkable during perioperative stages. After
an average follow-up of 46 months, only 1 of 14 patients with
benign diseases had a recurrence following the resection of a pleo-
morphic adenoma. Of seven patients with malignant tumours, five
are alive with no evidence of disease.
Conclusion:
Most of benign lateral skull base tumours can be
removed surgically with a low rate of complications and recur-
rence. However, malignant neoplasms carry a poor prognosis and
a low rate of disease-free survival.
http://dx.doi.org/10.1016/j.ijom.2017.02.476L
ow-dose prophylaxis for Chinese haemophilia children
involving maxillary haemophilic pseudotumours
G.X. Yu
∗
, H. Zhu, R.H. Wu
Department of Stomatology, Beijing Children’s Hospital,
Capital Medical University, China
Background:
The incident of haemophilic pseudotumour in
patients with haemophilia is estimated to be 1–2%,
∼
5–10%
among them occurring in maxilla. Patients with maxillary
haemophilic pseudotumour often visit dental clinics with com-
plaints of orofacial swelling and/or gingival bleeding and most of
them were misdiagnosed to be malignant tumours — they then
undergo repeated biopsies and invasive surgeries that is harmful
to children’s craniofacial upgrowth. Therefore, it is important to
improve diagnostic accuracy and provide timely treatment.
Methods:
There were seven cases of maxillary haemophilic pseu-
dotumour at our hospital between 2006 and 2014, with 6 cases of
haemophilia A and 1 case of haemophilia B. We retrospectively
analysed patients’ medical histories, physical examinations and
laboratory and image information. We treated the patients with
replacement therapy, most of them we choose the low-dose pro-
phylaxis (10–20 U/kg, QW), swelling and pain subsided in six
patients and one patient underwent surgery without replacement
therapy. We then observed the evolution of replacement treatment,
clinical and image observations.
Results:
(1) Diagnosis: five patients initially presented at other hospitals
were misdiagnosed as malignant tumours.
(2) After short-term (three to six months) low-dose prophylaxis,
recovery rate was 86% patients (assessed by clinicians and
radiologists).
Conclusion:
The oral surgeons should know more about
haemophilic pseudotumours, low-dose prophylaxis will be pre-
scribed for paediatric patients because of its clinical success,
noninvasive and effective for the haemophilic pseudotumours
involving the maxilla.
http://dx.doi.org/10.1016/j.ijom.2017.02.477




